Summary A comparison has been made of the weight loss produced by tumour necrosis factor (TNF) (cachectin) with that produced by a restricted food and water intake (pair-fed controls), and by mitozolomide, a drug which in toxic doses induces weight loss with a similar decrease in nutrient and water intake. When administered as two separate injections over a 24h period (acute administration) TNF produced a doserelated weight reduction that was accompanied by and directly proportional to a decrease in both food and water intake. When administered daily by i.v. injection over a 5-day period (chronic administration) the major weight loss was found to occur during the first 24h after injection and thereafter the weight of treated mice increased toward that of controls. Acute administration of TNF produced hypoglycaemia that was more severe than observed with either mitozolomide or in pair-fed controls, a reduction in the circulatory level of free fatty acids (FFA) and an increase in plasma triglycerides, while mitozolomide and pair-feeding had no effect on the level of blood glucose or plasma triglycerides. Body composition analysis showed a loss of adipose tissue in TNF-injected and pair-fed animals after both acute and chronic treatment. Acute administration of TNF also induced a decrease in the total body water content of treated aniimals which was similar to pair-fed controls. It is concluded that the weight loss produced by TNF arises from a combination of semi-starvation and a reduced water intake, and that the effect only occurred with the first administration of TNF.
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Cachexia is often reported as the most frequent cause of death in cancer patients (Robbins, 1962) and is characterized by the development of progressive weakness, weight loss and wasting. The frequency of cancer cachexia varies with tumour type, with gastrointestinal cancers and lung cancer having the greatest incidence (Strain, 1979) . Cachexia may occur with a small primary tumour and may precede the clinical diagnosis. The weight loss associated with cachexia may be accompanied by marked anorexia (Garrattini et al., 1980) . However, cancer cachexia is more like the condition produced by a major injury or sepsis, rather than that due to simple starvation (Brennan, 1977) . Anorexia seems to be only a partial cause of the wasting process, since in both rat and man loss of both muscle and adipose tissue frequently precedes a fall in food intake (Costa, 1963) . This suggests that metabolic disturbances within the tumour or the host tissues also contribute.
Several tumour-associated factors with a possible significance in the aetiology of the cachectic syndrome have been reported. Most recently a macrophage product, cachectin, has been suggested to orchestrate the complex metabolic changes that lead to cachexia. Cachectin has been shown to inhibit lipoprotein lipase activity in adipose tissue resulting in a marked elevation of plasma very low density lipoprotein (Beutler et al., 1985a) . Cachectin is an acidic protein which has been shown to be homologous to tumour necrosis factor (TNF) (Beutler et al., 1985b) , a macrophage product of molecular weight 17,000 that can be induced by endotoxin and other microbial products. When mice were passively immunized with a highly specific polyclonal rabbit antiserum directed against murine TNF they were protected against the lethal effect of the endotoxin lypopolysaccharide produced by E. coli (Beutler et al., 1985c) . This suggests that cachectin/TNF is one of the principal mediators of the lethal effect of endotoxin. In addition a considerable amount of evidence has implicated cachectin as a central mediator of the wasting that accompanies chronic invasive disease states (Beutler & Cerami, 1986) . Animals inoculated intramuscularly with a rodent tumour cell line which continuously secretes human TNF were recently shown to develop severe cachexia and weight loss (Oliff et al., 1987) . compared the parameters contributing to weight loss produced by human recombinant TNF with that in pair-fed animals and in animals injected with mitozolomide, a drug which in toxic doses also induces weight loss with a decrease in nutrient and water intake. The effects of acute and of chronic administration of TNF on NMRI mice are compared.
Materials and methods

Animals
Pure strain NMRI mice (age 6-8 weeks) were purchased from Banting and Kingman, Hull, UK, and were fed ad lib. a rat and mouse breeding diet (Pilsbury's, Birmingham, West Midlands, UK). All animals were given free access to food and water and both food and water intake were monitored daily. TNF-treated, pair-fed and mitozolomide-treated mice; bp<0.001 from controls (no treatment); CP<0.001 from arachis oil +10% DMSO infused controls; dp <0.001 from saline infused on pair-fed controls.
arachis oil containing 10% DMSO. Body weights and food and water intake were monitored and blood was removed by cardiac puncture from animals under anaesthesia 24h after the injection. Day of injection Difference in food (kcal mouse -') and water (ml) consumption Figure 5 Variation of weight loss (g) during a 24h period after administration of TNF with the difference in food (Kcal mouse-') and water (ml) consumption between a saline infused group and TNF treated groups. The results were fitted to a linear model by means of a least squares analysis (r= -0.92). increased consumption towards the levels found in the controls. The initial decrease in food and water intake is directly proportional to the decrease in body weight of the animals over the first 24h ( Figure 5 ). Animals given the same amount of food and water as that consumed by those injected with the highest concentration of TNF (7.5 x 107U kg-1) lost the same amount of weight over a 24 h period (Table I) . Mitozolomide is a cytotoxic drug, which at a concentration of 20 mg kg-1 causes general malaise and a decrease in food and water consumption equal to that obtained with 7.5 x 107 U kg -of TNF. The results in Table I show that there is no significant difference between the weight loss produced by mitozolomide and the equivalent concentration of TNF, suggesting that weight loss produced by TNF may be due to a generalized cytotoxicity. TNF treated mice show a highly significant hypoglycaemia 60 to 90 min after the second of 2 injections over a 24 h period, but not after 5 daily injections of TNF ( Figure 6 , Table I ). The TNF-induced hypoglycaemia is directly proportional to both the decrease in body weight (Figure 7 ) and and water (ml) consumption Figure 8 Variation of blood glucose concentration (mg 100ml-') with the difference of food (Kcal mouse-') and water (ml) pronounced than observed in weight-losing, pair-fed or mitozolomide-treated animals (Table I) . Marked hypertriglyceridemia is observed after acute administration of TNF ( Figure 9 , Table I ) and may be either due to inhibition of lipoprotein lipase activity, or to increased hepatic triglyceride synthesis (Feingold et al., 1987) . This increase in triglyceride levels is also directly proportional to the decrease in food and water consumption of treated animals as compared to control (r= -0.93). In contrast, pair-feeding and mitozolomide induced no significant changes in plasma triglyceride levels of treated animals. Plasma levels of FFA were reduced after acute TNF administration, but not after chronic administration (Figure 10 ).
The decrease in body weight was accompanied by a doserelated decrease in total body fat after both acute and chronic administration of TNF when compared with saline infused controls (Table II) . There was no difference in body fat content between the TNF treated and pair-fed controls. There was a decrease in total body water content after acute administration, but an increase was observed after 5 daily injections of TNF, when compared with saline infused controls. There was no difference in body water between TNF treated, pair-fed or mitozolomide treated animals. No change in thigh and gastrocnemius muscle content was observed after either acute or chronic administration of TNF. No change was observed in the body composition of (Blick et al., 1987) . However, progressive weight loss has been observed in mice bearing CHO cells transfected with the human TNF/ cachectin gene (Oliff et al., 1987) . This weight loss appeared to be due, at least in part, to reduced food consumption.
The weight loss induced by TNF appears to be directly related to the decrease in food and water consumption since animals fed the same amount of food and water lost the same amount of weight as the TNF treated group. In addition the body composition of the pair-fed group did not differ significantly from the TNF treated animals. No muscle breakdown occurred either after semi-starvation or after chronic administration of TNF at any of the concentrations employed.
The initial weight loss produced by TNF is associated with a marked and possibly life-threatening hypoglycaemia. While administration of lipopolysaccharide has been shown to induce hypoglycaemia, Satomia et al. (1985) reported no hypoglycaemia in mice administered highly purified TNF. However, Kettlehut et al. (1987) have recently demonstrated large biphasic changes in blood glucose levels after TNF induce hypoglycaemia, Satomi et al. (1985) Body water content in g; 2Body fat content in g; 3Left thigh and left gastrocnemius muscles in g; aP<0.01 from controls -no treatment; bp <0.05 from controls -i.v. saline; CP<0.01 from controls -arachis oil; dp <0.01 from controls -i.v. saline. metabolic perturbations induced by TNF. The observed hypoglycaemia is probably due to a direct action of TNF, and not merely due to a decrease in food and water consumption since the decrease in blood glucose is much more pronounced in TNF injected animals (7.5 x 107 U kg-1) than in pair-fed mice, even though the latter consumed the same amount of food and water, or in mitozolomide-treated mice despite a decrease in body weight with a decrease in nutrient intake. This severe hypoglycaemia could possibly be due to TNF stimulating glucose uptake and oxidation. Semb et al. (1987) has recently shown that the suppression of lipoprotein lipase activity by TNF is confined to adipose tissue and that increased enzyme activity is observed in several other tissues, most notably the liver and also in plasma. Although fasting also leads to a decrease in lipoprotein lipase activity in epididymal adipose tissue the effect of TNF on adipocyte gene expression differs from that in the fasted state.. We have observed a marked hypertriglyceridemia and a decreased level of FFA in mice 60 to 90 min after the second of two injections of human TNF over a 24 h period. This hypertriglyceridemia probably arises from an inhibition of adipocyte lipoprotein lipase, since the pool of plasma triglyceride is comparatively small and a minor impairment of the triglyceride removal mechanism would probably increase the size of this plasma pool (Nilsson-Ehle, 1980) . Although there was no correlation with the increase in triglyceride levels and the weight loss of mice, the decrease in plasma FFA observed was directly proportional to the weight loss in TNF-treated mice. Lipoprotein lipase inhibition and hence increased plasma triglyceride levels is due to a direct action of TNF and not merely due to a decrease in nutrient intake as mitozolomide-treated and pair-fed mice showed no changes in the level of circulating triglycerides.
The results suggest that the weight loss produced by TNF appears to arise from an anorexic or toxic effect of this agent, and that animals become refractory to subsequent administration of this cytokine.
